AbbVie Inc. (ABBV) traded at EUR 232.75 in after-hours trading on September 29, 2026, representing a slight decline of 0.47% against the prior close of EUR 233.85. The stock movement occurred following market hours and reflects minor volatility relative to the previous session's closing price.
In strategic developments, AbbVie announced a new partnership with Valkai, a life sciences artificial-intelligence platform, aimed at enhancing its clinical development capabilities. This collaboration is designed to deploy purpose-built AI tools across targeted areas of clinical research, with the specific goal of improving operational efficiency and accelerating the generation of critical insights for drug discovery processes.
On the regulatory front, AbbVie received approval from the U.S. Food and Drug Administration (FDA) for JUVMO (tavapadon) to treat adults with Parkinson's disease. The company plans to make this selective D1/D5 receptor agonist available to patients in the United States starting in October 2026, marking a significant expansion into its neurology portfolio.
📉 AbbVie stock closed down 0.47% at EUR 232.75 after-hours on Sept 29, 2026.
🤝 AbbVie partners with Valkai to integrate AI into clinical development workflows.
⚡ Collaboration deploys purpose-built AI to speed up insights in targeted research areas.
✅ FDA approved JUVMO for treating adults with Parkinson's disease.
📅 AbbVie expects U.S. launch of JUVMO in October 2026.
📉 AbbVie stock closed at EUR 232.75 after-hours on September 29, 2026, down 0.47% from the prior close of EUR 233.85.
🤝 The company announced a strategic partnership with Valkai to integrate artificial intelligence into its clinical development workflow.
⚡ This collaboration aims to deploy purpose-built AI capabilities to improve efficiency and speed up insights in targeted clinical research areas.
✅ AbbVie secured FDA approval for JUVMO (tavapadon) for the treatment of adults with Parkinson's disease.
📅 The company expects to launch JUVMO for U.S. patients in October 2026 following regulatory clearance.
Bullish Signals
FDA approved JUVMO for Parkinson's treatment.
Launching JUVMO in US by Oct 2026.
Risk Factors
Stock fell 0.47% to EUR 232.75 in after-hours trading.
Bullish Signals
AbbVie secured FDA approval for JUVMO (tavapadon), a selective D1/D5 receptor agonist, expanding its treatment options for adults with Parkinson's disease.
The company plans to launch the newly approved drug JUVMO in the U.S. market in October 2026, creating new revenue potential in the neurology segment.
Risk Factors
AbbVie stock declined 0.47% in after-hours trading on September 29, 2026, closing at EUR 232.75 versus a prior close of EUR 233.85.
AbbVie (ABBV) announced that the FDA has approved Juvmo, a new once-daily tablet containing tavapadon for treating Parkinson's disease. This approval marks a significant regulatory milestone as Juvmo is the first and only selective D1/D5 receptor agonist approved for this condition, offering a distinct mechanism of action compared to existing dopamine agonists that primarily target D2/D3 receptors.
The drug addresses critical limitations in current Parkinson's therapies by providing an alternative or adjunct treatment to levodopa. Clinical data from the TEMPO trial program indicates that Juvmo can help slow the progression of disease-related complications, such as dyskinesia and motor fluctuations. Specifically, 93% of participants did not require an increase in their levodopa dose after 85 weeks of treatment, compared to a worsening trend in the placebo group.
In terms of efficacy, patients taking Juvmo experienced a 22% to 23% improvement in daily living scores relative to baseline, while the placebo group declined by 12%. For those already on levodopa, the drug increased 'on' time by 1.7 hours versus 0.6 hours for placebo and reduced 'off' time by 1.9 hours versus 0.9 hours. AbbVie projects that Juvmo will be available to patients in the U.S. starting in October 2026.
The safety profile was described as favorable, with side effects mostly being mild to moderate, including nausea, headache, and dizziness. While dyskinesia and hallucinations were noted as common side effects when combined with levodopa, AbbVie's Chief Scientific Officer characterized this approval as the first major dopaminergic breakthrough for Parkinson's in decades, a sentiment echoed by external experts and patient advocacy groups.
📈 FDA approved Juvmo, AbbVie's first selective D1/D5 agonist for Parkinson's disease.
📊 93% of patients maintained stable levodopa dosing after 85 weeks on Juvmo.
⚡ TEMPO trials showed 22-23% improvement in daily living scores versus placebo decline.
🕒 Drug increased 'on' time by 1.7 hours and reduced 'off' time by 1.9 hours.
📅 AbbVie confirms U.S. availability for Juvmo starting October 2026.
📈 The FDA approved Juvmo (tavapadon), AbbVie's first selective D1/D5 receptor agonist for Parkinson's disease, distinguishing it from existing D2/D3-targeting therapies.
📊 Clinical data shows 93% of patients maintained stable levodopa dosing after 85 weeks on Juvmo, compared to a worsening trend in the placebo group.
⚡ Patients treated with Juvmo saw a 22-23% improvement in daily living scores versus a 12% decline for the placebo group in the TEMPO trials.
🕒 The drug increased 'on' time by 1.7 hours and reduced 'off' time by 1.9 hours compared to placebo in patients already taking levodopa.
📅 AbbVie confirmed that Juvmo will be available to U.S. patients starting in October 2026, providing a new treatment option for motor symptom control.
⚠️ Common side effects include nausea, headache, and dizziness; dyskinesia and hallucinations were observed when combined with levodopa but the overall safety profile was deemed favorable.
Bullish Signals
FDA approved Juvmo, first D1/D5 agonist for Parkinson's.
Bullish Signals
AbbVie secured FDA approval for Juvmo, a novel once-daily tablet that is the first selective D1/D5 receptor agonist approved for Parkinson's disease.
Clinical trials demonstrated that 93% of patients on Juvmo did not need to increase their levodopa dose after 85 weeks, addressing a key limitation of current therapies.
The drug showed statistically significant efficacy with a 22-23% improvement in daily living scores compared to a 12% decline in the placebo group.
Juvmo extended 'on' time by 1.7 hours and reduced 'off' time by 1.9 hours versus placebo, offering substantial benefits for patients on existing levodopa regimens.
AbbVie's Chief Scientific Officer described the approval as a major dopaminergic breakthrough for Parkinson's in decades, validating the strategic value of the asset.
The European Commission has granted approval for AbbVie's new therapy designed to treat active polyarticular juvenile idiopathic arthritis (pJIA) in DMARD-inadequate responders. This regulatory milestone specifically covers patients aged two years and older, marking a significant expansion of the drug's authorized use within the European market.
This approval represents a major strategic win for AbbVie as it solidifies its position in the pediatric rheumatology space with a novel treatment option. The decision validates the efficacy and safety profile of the therapy under European standards, potentially opening new revenue streams and strengthening the company's pipeline of approved biologics and small molecules.
The regulatory clearance is expected to facilitate broader market access across Europe, allowing AbbVie to commercialize the therapy in multiple jurisdictions following this initial approval. This development underscores the company's continued success in developing targeted therapies for rare and complex autoimmune conditions, contributing to its long-term growth strategy.
🇪🇺 EC approves therapy for active polyarticular juvenile idiopathic arthritis in DMARD-IR patients aged two+.
👶 Expands authorized population to include young children as young as two years old.
💊 Validates efficacy and safety of novel treatment for specific pediatric rheumatology subset.
📈 Facilitates commercialization across multiple European jurisdictions, driving future revenue growth.
🏆 Reinforces leadership in developing targeted therapies for rare and complex autoimmune diseases.
🇪🇺 The European Commission has officially approved AbbVie's therapy for active polyarticular juvenile idiopathic arthritis in DMARD-IR patients aged two and older.
👶 This regulatory milestone expands the drug's authorized patient population to include young children as young as two years old.
💊 The approval validates the efficacy and safety of AbbVie's novel treatment for a specific subset of pediatric rheumatology patients.
📈 This decision is expected to facilitate commercialization across multiple European jurisdictions, potentially driving future revenue growth.
🏆 The regulatory win reinforces AbbVie's leadership in developing targeted therapies for rare and complex autoimmune diseases.
Bullish Signals
EC approval expands market access for new arthritis therapy.
Validates efficacy in critical pediatric DMARD-inadequate responders.
The European Commission's approval of the new therapy for active polyarticular juvenile idiopathic arthritis represents a significant regulatory milestone that expands market access.
This approval specifically targets DMARD-inadequate responders aged two and older, validating the drug's efficacy in a critical pediatric patient population.
The successful European clearance strengthens AbbVie's pipeline of approved biologics and small molecules, contributing to its long-term growth strategy in rare diseases.
AbbVie (NYSE: ABBV) has diversified its pipeline by acquiring a stake in ADARx Pharmaceuticals during the company's IPO, gaining exposure to RNA interference drug candidates for rare disease indications. Simultaneously, Health Canada granted marketing authorization for AbbVie's EPKINLY for adults with relapsed or refractory follicular lymphoma, expanding its oncology franchise into later-line hematology care.
These strategic moves align with AbbVie's central narrative of replacing revenue from aging blockbusters like Humira and Imbruvica through a combination of internal research and business development deals. The ADARx investment signals the company's continued willingness to utilize minority stakes to secure optionality in newer modalities, while the EPKINLY approval directly supports the thesis that oncology must help offset erosion from older drugs.
However, these developments do not resolve concerns regarding the concentration of AbbVie's portfolio within a small cluster of major therapies. Analysts have flagged risks related to patent cliffs and pricing pressure, noting that new drugs only matter when they plug into a clear long-term replacement cycle. The article suggests weighing these pipeline moves against four specific warning signs identified for the company.
Simply Wall St analysts maintain a fair value target of $279 for AbbVie, emphasizing that successful execution on its pipeline and business development is critical to sustaining growth. The analysis highlights that while these new initiatives feed into the broader push for specialized, patent-protected treatments, investors must monitor how effectively management can execute this strategy amidst market challenges.
AbbVie successfully secured Health Canada marketing authorization for EPKINLY, expanding its oncology franchise into later-line hematology care.
The company acquired a stake in ADARx Pharmaceuticals during the IPO, demonstrating continued commitment to business development and exposure to RNA interference therapies.
Risk Factors
AbbVie remains concentrated in a small cluster of major therapies, creating vulnerability to patent cliffs and pricing pressure.
The company faces the ongoing challenge of replacing revenue from aging blockbusters like Humira and Imbruvica through its pipeline.
AbbVie Inc. shares approached a record high on September 24, 2026, trading at USD 265.07 after the company reported strong second-quarter financial results. The quarterly earnings per share (EPS) beat analyst consensus estimates by USD 0.04, reaching USD 3.65 against an expected USD 3.61. This positive performance contributed to a year-over-year revenue increase of 10.2%, with total revenue climbing to USD 16.99 billion compared to the prior year.
MarketBeat data highlights that AbbVie is successfully navigating its transition from Humira-era revenue by leveraging newer growth products while maintaining robust quarterly earnings momentum. The stock currently trades just 1.60% below its 52-week high of USD 269.39, reflecting investor confidence in the company's valuation and recent operational execution. Analyst consensus remains Moderate Buy with an average price target of USD 276.64, suggesting potential upside from current levels.
Looking ahead to the third quarter, AbbVie has provided EPS guidance ranging between USD 3.840 and USD 3.880 for investors to track against upcoming results. The company's market capitalization stands at approximately USD 468 billion as of late September 2026. While analyst price targets vary, with HSBC raising its target to USD 315, the overall sentiment remains positive driven by solid financial beats and strategic product transitions.
📈 Stock traded at $265.07, just 1.60% below its 52-week high.
💰 Q2 EPS beat estimates by $0.04 at $3.65 per share.
📊 Revenue grew 10.2% YoY to $16.99 billion, beating consensus.
🔄 Successfully replacing Humira revenue while preserving earnings momentum.
🎯 Analysts see 4.36% upside with a $276.64 average price target.
📈 AbbVie stock reached USD 265.07 on September 24, 2026, trading just 1.60% below its 52-week high of USD 269.39.
💰 The company reported Q2 2026 EPS of USD 3.65, beating the consensus estimate of USD 3.61 by USD 0.04.
📊 Revenue grew 10.2% year over year to reach USD 16.99 billion, exceeding the USD 16.80 billion consensus.
🔄 AbbVie is successfully replacing Humira-era revenue with newer growth products while preserving earnings momentum.
🎯 Analysts maintain a Moderate Buy consensus with an average price target of USD 276.64, implying 4.36% upside.
📅 HSBC raised its price target from USD 300 to USD 315 and maintained a Buy rating on the stock.
🔮 AbbVie set Q3 2026 EPS guidance between USD 3.840 and USD 3.880 for future investor comparison.
📉 Daily trading volume was 3,429,067 shares with a session range of USD 263.09 to USD 267.41.
Bullish Signals
Stock at $265.07, just 1.60% below 52-week high of $269.39.
Bullish Signals
AbbVie stock reached USD 265.07 on September 24, 2026, trading just 1.60% below its 52-week high of USD 269.39.
The company reported Q2 2026 EPS of USD 3.65, beating the consensus estimate of USD 3.61 by USD 0.04.
Revenue grew 10.2% year over year to reach USD 16.99 billion, exceeding the USD 16.80 billion consensus.
Analysts maintain a Moderate Buy consensus with an average price target of USD 276.64, implying 4.36% upside from current levels.
HSBC raised its price target from USD 300 to USD 315 and maintained a Buy rating on the stock.
Zacks Investment Research compares Pfizer (PFE) and AbbVie (ABBV), concluding that AbbVie currently offers a more attractive opportunity based on fundamentals. The analysis highlights AbbVie's successful navigation of Humira's loss of exclusivity, with its newer immunology drugs Skyrizi and Rinvoq generating over $14.6 billion in sales in the first half of 2026 and expected to reach combined sales above $31 billion for the full year.
AbbVie is projected to deliver more than 20% growth in 2026, supported by strong momentum in immunology, neuroscience, oncology, and aesthetics. The company expects total revenues to rise around 10% in 2026, driven by share gains in growing markets for its core franchises. Conversely, Pfizer faces a significant patent cliff later this decade with key products like Eliquis and Xeljanz facing expirations, expected to hurt sales by approximately $1.1 billion in 2026.
While Pfizer's stock has risen 13.2% year-to-date, AbbVie has jumped 16.0%, trading at a forward P/E of 17.01 compared to Pfizer's 9.56. Analyst consensus estimates for AbbVie imply a 40.5% increase in 2026 earnings, whereas Pfizer's estimates suggest a slight decrease. Despite both stocks holding a Zacks Rank #3 (Hold), the article favors AbbVie due to its visible growth profile and ability to offset blockbuster declines with new product launches.
📈 AbbVie expects combined Skyrizi and Rinvoq sales over $31B in 2026.
📉 Stock jumped 16% YTD with forward P/E of 17.01.
⚠️ Faces Humira biosimilar erosion and soft Aesthetics unit sales.
💰 Offers 1.9% dividend yield versus Pfizer's higher 6.1%.
🔬 Bolstering pipeline via Apogee Therapeutics acquisition for immunology assets.
📈 AbbVie expects combined Skyrizi and Rinvoq sales of more than $31 billion in 2026, representing over 20% growth for the year.
💊 Pfizer faces a significant patent cliff later this decade with key products like Eliquis and Xeljanz facing expirations expected to hurt sales by approximately $1.1 billion in 2026.
📉 AbbVie's stock has jumped 16.0% year-to-date, outperforming Pfizer's 13.2% gain and trading at a forward P/E of 17.01 versus Pfizer's 9.56.
🔬 Pfizer plans an extensive phase III program for berobenatide, targeting the first potential approval in 2028 to drive growth in obesity and related comorbidities.
📊 Zacks consensus estimates for AbbVie imply a 40.5% increase in 2026 earnings, while Pfizer's estimates suggest a slight decrease of 7.5%.
🏥 AbbVie is bolstering its pipeline with the recent acquisition of Apogee Therapeutics to strengthen late-stage immunology assets.
⚠️ AbbVie faces near-term headwinds including Humira biosimilar erosion and soft sales in its Aesthetics unit due to macroeconomic challenges.
📈 Pfizer expects high single-digit revenue CAGR starting from year-end 2028 as it recovers from the decline of COVID-related products.
💰 AbbVie offers a dividend yield of 1.9%, while Pfizer provides a significantly higher yield of 6.1%.
Bullish Signals
Skyrizi/Rinvoq sales projected to exceed $31B in 2026.
Total revenue expected to rise ~10% in 2026.
Stock jumped 16.0% YTD, outperforming industry and Pfizer.
Robust pipeline with key data readouts and approvals coming.
Successfully replaced Humira with two successful immunology drugs.
Risk Factors
J&J's Icotyde launch increases competition for Skyrizi.
Competitive pressure may impact Skyrizi prescription trends.
Bullish Signals
AbbVie expects combined Skyrizi and Rinvoq sales of more than $31 billion in 2026, with the drugs generating $14.6 billion in sales in the first half alone.
The company expects total revenues to rise around 10% in 2026, backed mainly by significant momentum in immunology and neuroscience products delivering share gains.
AbbVie's stock has jumped 16.0% year-to-date, outperforming the industry return of 12.7% and Pfizer's 13.2% gain.
The company boasts a robust pipeline with important data readouts, regulatory submissions, and approvals expected over the next couple of years.
AbbVie has successfully navigated Humira's loss of exclusivity by launching two other successful new immunology medicines that are performing extremely well.
Risk Factors
The launch of J&J's new oral pill Icotyde has increased competitive pressure for Skyrizi, which can impact the product's prescription trends.
AbbVie Inc. closed its shares at USD 265.21 on the NYSE on September 22, 2026, marking a modest 0.3 percent gain. The company reported strong second-quarter financial results with revenue rising 10.2 percent year over year to USD 16.99 billion and earnings per share (EPS) reaching USD 3.65, which beat analyst consensus estimates of USD 3.61 for EPS and USD 16.80 billion for revenue.
A significant regulatory milestone occurred when the European Commission approved RINVOQ for pediatric arthritis, adding a new indication to AbbVie's immunology portfolio. This approval is viewed as a concrete commercial step toward diversifying growth beyond its evolving portfolio, although the immediate market reaction was limited to a small daily price increase despite the stock trading near its yearly high.
Looking ahead, AbbVie provided adjusted EPS guidance for the third quarter of 2026 ranging between USD 3.84 and USD 3.88. Analysts maintain a Moderate Buy rating with an average price target of USD 276.64, suggesting potential upside from the current closing price. The company's market capitalization stands at approximately USD 469.10 billion as of September 22, 2026.
📈 ABBV stock closed up 0.3% at $265.21 with $469.1B market cap.
💰 Q2 revenue surged 10.2% YoY to $16.99B, beating estimates.
📊 EPS reached $3.65, surpassing analyst expectations of $3.61.
✅ European Commission approved RINVOQ for pediatric arthritis use.
🔮 Q3 adjusted EPS guidance set between $3.84 and $3.88.
📈 AbbVie stock closed at USD 265.21 on the NYSE, up 0.3 percent, with a market cap of approximately USD 469.10 billion.
💰 Q2 2026 revenue surged 10.2 percent year over year to USD 16.99 billion, significantly beating consensus estimates.
📊 EPS for the quarter reached USD 3.65, surpassing analyst expectations of USD 3.61 and showing strong growth from the prior year.
✅ The European Commission granted approval for RINVOQ in pediatric arthritis, expanding the drug's commercial potential.
🔮 AbbVie issued Q3 2026 adjusted EPS guidance between USD 3.84 and USD 3.88, providing clear forward-looking targets.
📉 The stock traded near its 52-week high of USD 267.47 but remained slightly below the peak at close.
🎯 Analysts maintain a Moderate Buy rating with an average price target of USD 276.64, indicating potential upside.
Bullish Signals
Q2 revenue hit $16.99B, up 10.2% YoY.
EPS beat estimates at $3.65 vs $3.61.
Got EC approval for RINVOQ in pediatric arthritis.
Guided to Q3 2026 EPS of $3.84-$3.88.
Bullish Signals
AbbVie reported Q2 revenue of USD 16.99 billion, representing a robust 10.2 percent year-over-year increase that significantly exceeded analyst consensus.
The company beat EPS estimates with results of USD 3.65 versus the expected USD 3.61, demonstrating strong operational performance.
AbbVie received European Commission approval for RINVOQ in pediatric arthritis, adding a valuable new indication to its immunology portfolio.
The company provided clear Q3 2026 adjusted EPS guidance ranging from USD 3.84 to USD 3.88, signaling confidence in near-term earnings.
AbbVie Inc. shares opened at $265.06 on September 22, 2026, near its 52-week high of $267.47, following a significant regulatory win for its key growth product RINVOQ. The European Commission approved the drug for use in children with active polyarticular juvenile idiopathic arthritis, expanding the treatment setting for this biologic agent.
Financially, AbbVie reported strong performance for the quarter ended June 30, 2026, with revenue rising 10.2% year-over-year to $16.99 billion. The company delivered an earnings per share (EPS) of $3.65, beating analyst consensus estimates by $0.04 and topping revenue expectations by $0.19 billion.
Despite the positive quarterly results and new drug approval, coverage noted that the full-year EPS outlook was a slight miss against expectations. With a market capitalization of approximately $468.31 billion, the stock trades at a valuation where earnings disappointments are closely scrutinized by investors.
📈 AbbVie stock opened near 52-week high after pediatric RINVOQ approval.
💊 New pediatric arthritis indication adds growth segment for RINVOQ.
📊 Q2 revenue hit $16.99 billion, up 10.2% year-over-year.
💰 Q2 EPS of $3.65 beat estimates by $0.04.
⚠️ Full-year EPS outlook slightly misses current market expectations.
📈 AbbVie stock opened near its 52-week high of $267.47 following European Commission approval for RINVOQ in pediatric patients.
💊 The regulatory decision extends RINVOQ's use to children with active polyarticular juvenile idiopathic arthritis, adding a new growth segment.
📊 Q2 revenue reached $16.99 billion, representing a 10.2% increase from the prior-year period.
💰 The company reported EPS of $3.65 for the quarter ended June 30, 2026, beating consensus estimates by $0.04.
🎯 Revenue exceeded analyst expectations by $0.19 billion during the second quarter of fiscal year 2026.
⚠️ Analysts described the full-year EPS outlook as a slight miss against current market expectations.
Bullish Signals
European Commission approved RINVOQ for children's arthritis.
Q2 revenue grew 10.2% YoY to $16.99B.
Beat EPS consensus by $0.04 at $3.65.
Risk Factors
Full-year EPS outlook missed expectations.
Stock near 52-week high limits upside.
Bullish Signals
AbbVie received European Commission approval for RINVOQ in children with active polyarticular juvenile idiopathic arthritis, expanding its key growth product portfolio.
AbbVie Inc. shares rallied to trade near their 52-week high of $267.47, reaching approximately $263.52 on September 21, 2026, following the announcement of a multi-year collaboration with Iambic. This partnership leverages artificial intelligence to accelerate small molecule drug discovery across AbbVie's key therapeutic areas, including immunology, neuroscience, and oncology.
The strategic deal aims to identify first-in-class and best-in-class therapies while utilizing digital tools to compress discovery timelines. By integrating Iambic's AI-driven platform, AbbVie intends to deepen its pipeline in these critical franchises and sustain its growth trajectory as it transitions away from its legacy Humira franchise.
Financially, the company reported strong double-digit revenue growth in Q2 2026, driven by the scaling of newer assets like Skyrizi and Rinvoq. This positive financial backdrop supports AbbVie's status as a dividend payer with a yield around 2.59%, reinforcing investor confidence in the balance between growth investment and shareholder returns.
Market data indicates heightened interest in the stock, with trading volume reaching 8.18 million shares compared to an average daily volume of 4.73 million. The market is currently pricing AbbVie based on a combination of its growing pipeline, ongoing dividend payments, and new AI-driven discovery initiatives.
📈 Stock trades near $267.47 high after Iambic AI drug discovery deal.
🤝 AI partnership accelerates small molecule discovery across immunology and oncology.
💰 Q2 2026 revenue grew double-digits as Humira transition continues.
📊 Skyrizi and Rinvoq assets scale successfully to support growth.
💵 Maintains ~2.59% dividend yield for income-focused investors.
📈 AbbVie stock gained value to trade near its 52-week high of $267.47 following the announcement of a multi-year AI drug discovery collaboration with Iambic.
🤝 The partnership applies artificial intelligence to small molecule drug discovery across immunology, neuroscience, and oncology to accelerate therapy identification.
🚀 AbbVie aims to use digital tools from the deal to compress discovery timelines and deepen its pipeline in key therapeutic franchises.
💰 The company reported strong double-digit revenue growth in Q2 2026 as it transitions beyond its legacy Humira franchise.
📊 New assets Skyrizi and Rinvoq are scaling successfully, supporting the company's growth trajectory alongside the new AI initiative.
💵 AbbVie maintains a dividend yield of approximately 2.59%, reinforcing its appeal to investors seeking both growth and income.
📉 Trading volume surged to 8.18 million shares on September 21, 2026, indicating heightened investor interest in the AI collaboration news.
Bullish Signals
Stock rallied near 52-week high of $267.47 after Iambic AI deal.
Q2 2026 revenue grew double-digits as Skyrizi and Rinvoq scaled.
Iambic partnership accelerates first-in-class small molecule therapy discovery.
Digital tools compress R&D timelines to improve pipeline efficiency.
Market cap $466.34B reflects confidence in strategic direction.
Bullish Signals
AbbVie stock rallied to trade near its 52-week high of $267.47 following the announcement of a multi-year AI drug discovery collaboration with Iambic.
The company reported strong double-digit revenue growth in Q2 2026, demonstrating successful scaling of newer assets like Skyrizi and Rinvoq.
The partnership with Iambic aims to accelerate the identification of first-in-class and best-in-class small molecule therapies across key therapeutic areas.
AbbVie is utilizing digital tools from the collaboration to compress discovery timelines, potentially improving efficiency in its R&D pipeline.
The stock traded at $263.52 with a market capitalization of approximately $466.34 billion, reflecting strong market confidence in the company's strategic direction.
AbbVie Inc. stock closed at USD 263.96 on September 18, 2026, showing a negligible 0.02% decline while trading near recent highs. The company maintains its status as an income-oriented large-cap pharmaceutical name with a declared quarterly dividend of USD 1.73 per share and an ex-dividend date set for October 15, 2026.
Valuation metrics indicate that AbbVie trades at a trailing price-to-earnings multiple of 74.6 times, which is approximately 18% above its five-year median, though the forward multiple is cited at 16.2 times based on next year's earnings expectations. Analyst sentiment remains broadly positive, with 32 of 39 tracked analysts maintaining a bullish stance on the stock.
The company's pipeline progress and commercial milestones, particularly in its migraine franchise, are expected to support growth following the loss of exclusivity on legacy products like Humira. Over the trailing twelve months, AbbVie shares have gained 18.91%, outpacing broader market benchmarks as investors weigh dividend income against elevated valuation expectations.
Market data from various platforms highlights that while a small minority of analysts remain cautious, the consensus view is that AbbVie's earnings and cash flows remain attractive in the medium term. Future quarterly results and clinical updates will be closely scrutinized to confirm whether pipeline contributions can sustain the current premium valuation.
📈 Stock closed at $263.96 with negligible decline and slight after-hours gain.
💰 Quarterly dividend of $1.73/share implies forward yield of about 2.6%.
📊 Trading at trailing P/E of 74.6x, 18% above five-year median.
👍 Analyst sentiment is strongly bullish with 32 of 39 ratings as Buy.
💊 Migraine franchise milestone adds growth to post-Humira portfolio.
📈 AbbVie Inc. stock closed at USD 263.96 on September 18, 2026, with a negligible 0.02% decline and an after-hours indication of USD 264.18.
💰 The company announced a quarterly dividend of USD 1.73 per share with an ex-dividend date of October 15, 2026, implying a forward yield of about 2.6%.
📊 Valuation metrics show AbbVie trading at a trailing P/E of 74.6x (18% above its five-year median) and a forward P/E of 16.2x based on next year's earnings.
👍 Analyst sentiment is strongly bullish, with 32 of 39 tracked analysts rating the stock as Buy and only 3.1% as Sell.
💊 AbbVie's migraine franchise recently achieved a notable regulatory and commercial milestone, adding growth to its post-Humira portfolio.
📈 Stock performance over the trailing twelve months shows a gain of 18.91%, outpacing many broader market benchmarks.
🔍 Investors note that AbbVie trades at an elevated valuation level where future quarterly results will be critical to sustaining the premium multiple.
Bullish Signals
Stock gained 18.91% over trailing twelve months.
32/39 analysts rate shares Buy for pipeline growth.
Declared quarterly dividend of USD 1.73 per share.
Risk Factors
P/E multiple of 74.6x is 18% above five-year median.
Pipeline must sustain premium after legacy product exclusivity loss.
Bullish Signals
AbbVie Inc. stock has delivered solid total returns over the last year, gaining 18.91% over the trailing twelve months and outpacing broader market benchmarks.
The company maintains a strong analyst consensus with 32 of 39 tracked analysts classifying shares as Buy, betting that post-Humira pipeline growth will accelerate.
AbbVie recently achieved a notable regulatory and commercial milestone for its migraine franchise, adding another growth leg to its portfolio of immunology and oncology assets.
The declared quarterly dividend of USD 1.73 per share reinforces the company's profile as an attractive income-oriented large-cap pharmaceutical name.
Risk Factors
AbbVie trades at a trailing price-to-earnings multiple of 74.6 times, which is roughly 18% above its five-year median, suggesting elevated valuation expectations.
The stock faces scrutiny as investors assess whether pipeline contributions can sustain the current premium valuation given the loss of exclusivity on legacy products.
AbbVie Inc. stock traded at USD 263.52 on September 19, 2026, holding near its 52-week high of USD 267.47 with a market capitalization of USD 466.34 billion. The company reported strong second-quarter financial results, posting adjusted earnings per share of USD 2.03 compared to USD 0.52 a year earlier, while revenue increased by 10.16 percent to reach USD 16.99 billion.
Analyst consensus for AbbVie stands at USD 277.31, representing a potential upside of approximately 5.64 percent from the current trading price, with ratings generally leaning towards Buy. However, valuation metrics present a mixed picture, as the GF Value model suggests the stock is trading at a 19.6 percent premium to its fair value of USD 220.69.
The pharmaceutical giant's shares saw a session volume of 8.18 million shares on September 19, with intraday activity reaching a high of USD 266.29. The next quarterly earnings report is scheduled for release on October 23, 2026, keeping investor attention focused on future guidance and performance trends.
📈 Stock closed at USD 263.52 below 52-week high of USD 267.47.
💰 Q2 revenue surged to USD 16.99 billion, up 10.16% year-over-year.
📊 Adjusted EPS jumped to USD 2.03 from USD 0.52 last year.
🎯 Analyst consensus target of USD 277.31 implies 5.64% upside.
⚖️ GF Value suggests fair price of USD 220.69 vs market price.
📈 AbbVie stock closed at USD 263.52 on September 19, 2026, trading just below its 52-week high of USD 267.47.
💰 Second-quarter revenue surged to USD 16.99 billion, marking a 10.16 percent year-over-year increase.
📊 Adjusted earnings per share jumped significantly to USD 2.03 in the second quarter compared to USD 0.52 last year.
🎯 Analyst consensus price target is set at USD 277.31, implying roughly 5.64 percent upside from current levels.
⚖️ Valuation models indicate overvaluation, with GF Value suggesting a fair price of USD 220.69 versus the market price of USD 264.02.
📉 Trading volume reached 8.18 million shares on September 19, reflecting active investor interest near yearly highs.
🗓️ The next earnings report is scheduled for release on October 23, 2026.
Bullish Signals
Revenue grew 10.16% to USD 16.99 billion.
Adjusted EPS tripled year-over-year to USD 2.03.
Stock trades near 52-week high of USD 267.47.
Analyst target implies 5.64% upside potential.
Risk Factors
Valuation shows 19.6% premium to fair value.
Stock at 52-week highs limits upside.
Bullish Signals
AbbVie reported robust second-quarter revenue growth of 10.16 percent to USD 16.99 billion, demonstrating strong top-line performance.
Adjusted earnings per share more than tripled year-over-year to USD 2.03, highlighting significant profitability improvement.
The stock is trading near its 52-week high of USD 267.47 with a market cap of USD 466.34 billion, indicating strong investor confidence.
Analyst consensus price target of USD 277.31 suggests potential upside of 5.64 percent from current trading levels.
Risk Factors
Valuation metrics suggest the stock is overvalued, with GF Value indicating a 19.6 percent premium to its calculated fair value of USD 220.69.
The stock price has reached near-52-week highs, which may limit immediate upside potential and increase sensitivity to any earnings miss.
AbbVie Inc. (ABBV) is a global biopharmaceutical company with a current dividend yield of 2.59% based on a $6.83 annual payout and a share price of $263.37. The company has increased its dividend for over 11 consecutive years, demonstrating a long history of commitment to shareholder returns despite recent earnings volatility.
The article highlights a significant concern regarding ABBV's trailing payout ratio of 189.7%, which indicates that current earnings alone do not cover the dividend payment. Analysts and investors are advised to scrutinize this metric, noting that free cash flow coverage and forward earnings estimates may provide a more accurate picture of dividend safety than trailing EPS in this specific context.
Historically, ABBV has shown strong dividend growth with a compound annual growth rate (CAGR) of 12.5% from 2013 to 2025. While the current yield is slightly above its five-year average, the elevated payout ratio creates pressure on sustainability if earnings do not expand or if the company faces setbacks in its blockbuster drug portfolio.
AbbVie's diversified therapeutic portfolio includes major products like HUMIRA, SKYRIZI, and RINVOQ across immunology, oncology, and neurology. The stock exhibits low volatility with a beta of 0.281, making it attractive to income investors seeking price stability, though the high payout ratio remains the primary risk factor for long-term dividend sustainability.
📈 ABBV offers a 2.59% dividend yield with $6.83 annual payout per share.
📉 Trailing payout ratio is 189.7%, exceeding current earnings coverage.
📊 Dividend growth streak spans over 11 years at a 12.5% CAGR.
🛡️ Stock shows low volatility with a beta of 0.281 for stability.
💊 Revenue driven by HUMIRA, SKYRIZI, and RINVOQ blockbuster drugs.
📈 ABBV offers a current dividend yield of 2.59% with an annual payout of $6.83 per share and a quarterly payment of $1.73.
📉 The company's trailing payout ratio stands at 189.7%, indicating that earnings alone do not currently cover the dividend payments.
📊 ABBV has maintained a streak of dividend growth for over 11 consecutive years, with a historical CAGR of 12.5% from 2013 to 2025.
🛡️ The stock displays low volatility with a beta of 0.281, appealing to income investors who prioritize price stability over capital gains.
💊 AbbVie's revenue is driven by a diversified portfolio including blockbuster drugs like HUMIRA, SKYRIZI, and RINVOQ across multiple therapeutic areas.
📅 The next ex-dividend date for ABBV is scheduled for October 15, 2026.
Bullish Signals
Dividend increased 11+ years.
Yield 2.59% vs 2.25% avg.
Beta 0.281 for stability.
Risk Factors
Payout ratio is 189.7%, risking dividend sustainability if earnings drop.
Dividend safety relies on free cash flow, not trailing EPS.
Bullish Signals
AbbVie has increased its dividend for over 11 consecutive years, demonstrating a strong track record of commitment to shareholder returns.
The current dividend yield of 2.59% is slightly above the company's five-year average of 2.25%, offering attractive income relative to historical norms.
ABBV exhibits low market volatility with a beta of 0.281, making it suitable for investors seeking price stability alongside dividend income.
Risk Factors
The trailing payout ratio is 189.7%, meaning current earnings alone do not cover the dividend, creating potential sustainability risks if earnings decline.
Investors must rely on free cash flow or forward earnings estimates rather than trailing EPS to accurately assess the safety of ABBV's dividend payments.
The article argues that AbbVie (NYSE: ABBV) is the superior dividend investment compared to Pfizer, citing a longer history of dividend growth and stronger revenue expansion. While Pfizer offers a higher current yield at 6.1%, AbbVie provides a more sustainable profile with a Dividend King status, having increased its quarterly dividend for 53 consecutive years.
AbbVie successfully navigated the expiration of its blockbuster drug Humira by pivoting to home-grown immunology assets, Skyrizi and Rinvoq. By 2025, these new drugs generated over $25 billion in combined annual sales, effectively replacing lost revenue and pushing total company revenue to record highs. This strategic transition allowed the company to return to mid- to high-single-digit top-line growth without a permanent structural hit.
In contrast, Pfizer faces significant patent cliffs between 2026 and 2028, exposing roughly $17 billion to $18 billion in annual revenue from core blockbusters like Eliquis and Ibrance. Although AbbVie carries more total debt at roughly $62 billion, its leverage is manageable due to strong cash flows from new products, whereas Pfizer's debt-to-equity ratio is over three times higher as it pays down obligations amidst legacy drug erosion.
Financial performance highlights include AbbVie's second-quarter sales of $16.9 billion, up 10.2% year over year, driven by Skyrizi ($5.5 billion) and Rinvoq ($2.52 billion). The company also recently acquired Apogee Therapeutics for $10.9 billion to expand its atopic dermatitis portfolio, further solidifying its growth trajectory against Pfizer's acquisition of Metsera for weight-loss therapies.
📈 AbbVie outperforms Pfizer with superior dividend growth and revenue expansion.
💰 AbbVie raised quarterly dividend 5.5% to $1.73 for 53 consecutive years.
💊 Skyrizi and Rinvoq replaced Humira, generating over $25 billion in sales.
📊 Q2 sales rose 10.2% year-over-year to $16.9 billion driven by immunology.
📈 AbbVie is identified as the smarter dividend buy over Pfizer due to a superior track record of dividend growth and revenue expansion.
💰 AbbVie has increased its quarterly dividend for 53 consecutive years, earning Dividend King status, with a recent 5.5% raise to $1.73 per share.
📉 Pfizer faces greater exposure to patent exclusivity loss between 2026 and 2028, risking roughly $17 billion to $18 billion in annual revenue from core blockbusters.
💊 AbbVie successfully replaced Humira revenue with home-grown assets Skyrizi and Rinvoq, which combined generated over $25 billion in sales by 2025.
📊 Q2 earnings showed AbbVie sales rising 10.2% year over year to $16.9 billion, driven primarily by its immunology portfolio.
💸 Pfizer's debt-to-equity level is more than three times that of AbbVie, creating greater pressure on cash-flow conversion as legacy drugs lose market share.
🤝 AbbVie is executing a multi-year portfolio pivot with recent acquisitions like Apogee Therapeutics ($10.9 billion) to capture new therapeutic areas.
📈 Over the past decade, AbbVie's revenue grew by more than 138% compared to Pfizer's growth of just over 18%.
Bullish Signals
Dividend King status with 53 consecutive years of increases.
Skyrizi and Rinvoq generated over $25B annual sales.
Q2 sales reached $16.9B, up 10.2% year-over-year.
Returned to mid- to high-single-digit top-line growth.
Acquired Apogee Therapeutics for $10.9 billion.
Risk Factors
Long-term debt is $62B vs Pfizer's $32.6B.
Bullish Signals
AbbVie has increased its quarterly dividend for 53 consecutive years, achieving Dividend King status with a recent 5.5% raise to $1.73 per share.
The company successfully navigated the Humira patent cliff by developing Skyrizi and Rinvoq, which combined generated over $25 billion in annual sales by 2025.
Second-quarter sales reached $16.9 billion, a 10.2% year-over-year increase driven by strong performance from its immunology drugs.
AbbVie returned to mid- to high-single-digit top-line growth after bridging the immunology drop-off without taking a permanent structural hit.
The company acquired Apogee Therapeutics for $10.9 billion to gain access to promising atopic dermatitis therapy zumilokibart.
Risk Factors
AbbVie carries more long-term debt, roughly $62 billion as of the second quarter, compared to Pfizer's $32.6 billion.
AbbVie (NYSE: ABBV) is positioned ahead of its July 31 Q2 earnings report with strong momentum driven by two blockbuster immunology drugs, Skyrizi and Rinvoq. These products combined generated $6.6 billion in revenue during the first quarter of 2026, effectively replacing Humira as the company's primary growth engines. Management has raised full-year guidance for both drugs to $21.6 billion and $10.2 billion respectively, signaling confidence that they will generate nearly $32 billion in annual sales.
The stock currently trades at a forward P/E of 18x with a PEG ratio of 0.43, presenting a valuation below the S&P 500 average while offering low volatility with a beta of 0.28. Wall Street consensus targets the stock at $267.79, slightly above the current price of $265.52, supported by 16 Buy and 8 Strong Buy ratings. The company recently increased its quarterly dividend by 5.5% to $1.73 per share, lifting full-year adjusted EPS guidance to a range of $14.08 to $14.28.
AbbVie has successfully navigated the patent cliff that rivals Merck and Pfizer are currently facing or will face in the coming years. While Humira revenue continues to decline due to biosimilar competition, the company's overall trajectory is defined by the rapid expansion of its newer portfolio. The upcoming earnings report on July 31 is expected to confirm whether these new products can sustain growth and support further increases to full-year guidance.
📈 AbbVie trades at forward P/E of 18x with PEG ratio of 0.43.
💰 Dividend raised 5.5% to $1.73; full-year EPS guidance lifted to $14.28.
🚀 Skyrizi and Rinvoq generated $6.6B Q1 revenue with strong growth.
🛡️ AbbVie crossed biosimilar patent cliff, positioning ahead of competitors.
🎯 Consensus price target is $267.79 with 24 Buy/Strong Buy ratings.
📈 AbbVie trades at a forward P/E of 18x with a PEG ratio of 0.43, offering growth prospects at a valuation below the S&P 500 average.
💰 The company raised its quarterly dividend by 5.5% to $1.73 per share and lifted full-year adjusted EPS guidance to $14.08-$14.28.
🚀 Skyrizi and Rinvoq combined generated $6.6 billion in Q1 2026 revenue, with Skyrizi growing 30.9% YoY and Rinvoq growing 23.3% YoY.
📊 Management raised full-year sales guidance for Skyrizi to $21.6 billion and for Rinvoq to $10.2 billion.
🛡️ AbbVie has already crossed the biosimilar patent cliff that Merck faces in 2028, positioning it ahead of key competitors.
📉 The stock exhibits low volatility with a beta of 0.28 compared to the broader market's higher risk profile.
🎯 Wall Street consensus price target is $267.79 across 16 Buy and 8 Strong Buy ratings from analysts.
💼 Immunology revenue grew 16.4% in Q1 as the two new drugs replaced Humira as the primary growth drivers.
Bullish Signals
Trades at 18x forward P/E with 0.43 PEG ratio.
Raised quarterly dividend 5.5% to $1.73/share.
Skyrizi and Rinvoq generated $6.6B Q1 revenue.
Raised full-year sales guidance for key drugs.
Beta of 0.28 offers low volatility growth.
Bullish Signals
AbbVie trades at a forward P/E of 18x with a PEG ratio of 0.43, offering attractive valuation relative to growth prospects and below the S&P 500 average.
The company increased its quarterly dividend by 5.5% to $1.73 per share and raised full-year adjusted EPS guidance to $14.08-$14.28, signaling strong income coverage.
Skyrizi and Rinvoq combined generated $6.6 billion in Q1 2026 revenue, with Skyrizi growing 30.9% YoY and Rinvoq growing 23.3% YoY.
Management raised full-year sales guidance for Skyrizi to $21.6 billion and for Rinvoq to $10.2 billion, projecting nearly $32 billion in annual sales.
The stock has a beta of 0.28, providing low volatility compared to the broader market while maintaining significant growth momentum.
Wall Street consensus price target is $267.79 across 16 Buy and 8 Strong Buy ratings, indicating strong analyst confidence in the current valuation.
AbbVie (ABBV) has established itself as a major cash-return engine, returning approximately $62 billion to shareholders over the last five years through dividends and buybacks. This total represents about 13.4% of the company's current market value and ranks as the 25th largest among all U.S. companies. The substantial capital returns are fueled by a highly profitable immunology portfolio that has successfully replaced older revenue streams with a new generation of blockbuster drugs.
The company's commercial durability is driven by SKYRIZI, which saw sales surge 24% to $5.5 billion in the most recent quarter, and RINVOQ, which climbed 24% to over $2.5 billion. These immunology products generated $18.21 billion in free cash flow over the last twelve months, supporting a history of potent shareholder returns including a +161% total stock return over five years, nearly double the S&P 500's performance.
Management maintains confidence in its growth drivers, forecasting SKYRIZI to generate $21.7 billion in global revenues for the full year. However, investors are debating whether high cash returns come at the expense of reinvestment, noting a price-to-earnings multiple of 72.9 and potential risks from an increasingly crowded development landscape in immunology where competitive inroads could alter the company's calculus.
📈 AbbVie returned $62B to shareholders over the last five years.
💰 Company generated $18.21B in free cash flow trailing twelve months.
🚀 SKYRIZI sales surged 24% to $5.5 billion in the latest quarter.
⚠️ Stock trades at a price-to-earnings multiple of 72.9, raising valuation concerns.
💼 AbbVie acquired Apogee Therapeutics to bolster its immunology portfolio.
📈 AbbVie returned $62 billion to shareholders over the last five years, ranking as the 25th largest cash returner among U.S. companies.
💰 The company generated $18.21 billion in free cash flow over the trailing twelve months, fueling its robust capital return machine.
🚀 SKYRIZI sales surged 24% to $5.5 billion in the most recent quarter, while RINVOQ sales climbed 24% to over $2.5 billion.
📊 AbbVie stock delivered a +161% total return over the past five years, significantly outperforming the S&P 500's +82% gain.
🎯 Management forecasts SKYRIZI will generate $21.7 billion in global revenues for the full year, supporting dividend commitments.
⚠️ The stock trades at a price-to-earnings multiple of 72.9, prompting debate over whether shares have become too expensive relative to growth.
🔬 Analysts probe risks regarding an increasingly crowded development landscape for AbbVie's key immunology drugs.
💼 Management recently announced a deal for Apogee Therapeutics to bolster its leading immunology portfolio.
Bullish Signals
AbbVie returned $62 billion to shareholders over the last five years, ranking as the 25th largest cash returner among all U.S. companies.
The company generated $18.21 billion in free cash flow over the trailing twelve months, demonstrating a highly profitable business model.
SKYRIZI sales surged 24% to $5.5 billion in the most recent quarter, while RINVOQ sales climbed 24% to over $2.5 billion.
Holding AbbVie stock produced a +161% total return over the past five years, nearly doubling the S&P 500's return.
Management forecasts SKYRIZI will generate $21.7 billion in global revenues for the full year, indicating strong commercial durability.
Risk Factors
The stock trades at a price-to-earnings multiple of 72.9, prompting debate over whether shares have become too expensive.
Analysts on the latest earnings call probed risks regarding an increasingly crowded development landscape for key drugs.
Investors face the risk that unexpected competitive inroads in immunology could quickly alter the company's cash return calculus.
AbbVie (NYSE:ABBV) has demonstrated strong financial performance in the second quarter, reporting revenue of nearly $17 billion, a 10.2% increase year-over-year. The company's growth is primarily driven by its blockbuster biologic drugs, with Skyrizi generating $5.5 billion and Rinvoq surpassing $2.5 billion in sales during the period.
Management has raised full-year earnings per share (EPS) guidance to a range of $13.87 to $14.07, reflecting confidence in the company's pipeline and execution capabilities. Analyst Piper Sandler recently increased its price target on AbbVie shares to $303 while maintaining an Overweight rating, citing the firm's robust long-term outlook.
Strategic initiatives are poised to further accelerate growth, including a $10.9 billion agreement with Apogee Therapeutics and the upcoming launch of Skyrizi as a subcutaneous formulation for Crohn's disease. The company continues to prioritize shareholder returns, having raised its annualized dividend to $6.92 from $6.56 in the prior year.
Looking ahead to 2027, AbbVie aims to achieve a share price of $325, which would imply a forward P/E multiple of approximately 23x. This target relies on sustained beat streaks, successful pipeline delivery, and favorable macroeconomic conditions to support the valuation expansion required to reach this level.
📈 AbbVie Q2 revenue rose 10.2% to nearly $17 billion.
💊 Skyrizi and Rinvoq sales grew 24% and 23.7% respectively.
🤝 AbbVie signed a $10.9 billion deal with Apogee Therapeutics.
📈 Management raised full-year EPS guidance to $13.87-$14.07.
💰 Annualized dividend increased to $6.92 per share.
📈 AbbVie reported Q2 revenue of nearly $17 billion, representing a 10.2% increase compared to the prior year.
💊 Skyrizi sales reached $5.5 billion in the quarter, marking a significant 24% growth rate.
💊 Rinvoq sales exceeded $2.5 billion, achieving a robust 23.7% increase during the same period.
📈 Management raised full-year EPS guidance to a range of $13.87 to $14.07.
🤝 AbbVie signed a $10.9 billion deal with Apogee Therapeutics to expand its portfolio.
💉 The company is preparing to launch Skyrizi as a subcutaneous injection for Crohn's disease.
💰 AbbVie increased its annualized dividend to $6.92, up from $6.56 in the previous year.
📈 Piper Sandler raised its price target on AbbVie shares to $303 with an Overweight rating.
🎯 Analysts project a potential share price of $325 by 2027 if growth targets are met.
📉 The current forward P/E multiple is approximately 18x, below the implied 23x at the $325 target.
Bullish Signals
Q2 revenue hit nearly $17B, up 10.2% YoY.
Skyrizi sales reached $5.5B, growing 24%.
Rinvoq sales surpassed $2.5B, up 23.7%.
Raised full-year EPS guidance to $13.87-$14.07.
Piper Sandler raised price target to $303.
Bullish Signals
AbbVie reported Q2 revenue of nearly $17 billion, a 10.2% increase year-over-year.
Skyrizi sales reached $5.5 billion in the quarter, growing by 24%.
Rinvoq sales surpassed $2.5 billion, achieving a 23.7% increase.
Management raised full-year EPS guidance to a range of $13.87 to $14.07.
Piper Sandler raised its price target on AbbVie shares to $303 with an Overweight rating.
The company signed a $10.9 billion deal with Apogee Therapeutics.
AbbVie increased its annualized dividend to $6.92, up from $6.56 in the prior year.
AbbVie (ABBV) reported strong financial performance in the second quarter of 2026, with total net revenues reaching $16.99 billion, a 10.2% increase year over year. This growth was driven primarily by its immunology and neuroscience franchises, specifically Skyrizi and Rinvoq, which generated a combined $8.03 billion in revenue for the quarter. These figures represent a successful transition away from Humira, which contributed only $756 million after losing US exclusivity to biosimilars.
The company demonstrated robust profitability with an adjusted gross margin of 84.7% and an adjusted operating margin of 48.3%. AbbVie declared a quarterly dividend of $1.73 per share, maintaining its status as a Dividend Aristocrat while managing substantial debt from the Allergan acquisition. Management also raised full-year 2026 revenue guidance by approximately $300 million to roughly $67.6 billion.
Strategically, AbbVie agreed to acquire Apogee Therapeutics for an equity value of roughly $10.9 billion to deepen its immunology franchise with a new extended half-life IL-13 antibody. The company also secured patent settlements extending US generic competition for Rinvoq until April 2037 and is pursuing regulatory approvals for new indications in Skyrizi and Rinvoq, including vitiligo and alopecia areata.
📈 Q2 2026 revenue hit $16.99B, up 10.2% operationally.
💊 Skyrizi and Rinvoq generated $8.03B combined quarterly revenue.
🛡️ US exclusivity for Rinvoq extended until April 2037.
🤝 Acquired Apogee Therapeutics for roughly $10.9 billion cash.
🎯 Raised full-year 2026 revenue guidance to ~$67.6B.
📈 AbbVie reported Q2 2026 total net revenues of $16.99 billion, representing a 10.2% operational increase year over year.
💊 Skyrizi and Rinvoq combined generated $8.03 billion in revenue for the quarter, significantly outpacing Humira's contribution of $756 million.
📉 Humira revenue fell 36.1% operationally to $756 million following the loss of US exclusivity in 2023.
🛡️ AbbVie settled patent challenges with generic filers, extending US exclusivity for Rinvoq until April 2037.
💰 The company declared a quarterly dividend of $1.73 per share, annualizing to a yield of approximately 2.8% at the reported price.
🤝 AbbVie agreed to acquire Apogee Therapeutics for roughly $10.9 billion in cash to expand its immunology pipeline.
📊 Adjusted diluted EPS rose 22.9% year over year to $3.65, reflecting strong underlying cash economics despite GAAP charges.
🔬 Skyrizi revenue reached approximately $5.5 billion in the quarter, up around 24% operationally from the prior year.
📈 Rinvoq passed $2.5 billion in quarterly revenue, growing 23.7% operationally as it expands into new indications.
🎯 AbbVie raised full-year 2026 revenue guidance by about $300 million to approximately $67.6 billion.
⚖️ The company maintained an adjusted operating margin of 48.3%, absorbing a 1.7 percentage point impact from acquired in-process R&D.
📉 AbbVie trimmed adjusted diluted EPS guidance slightly to reflect anticipated dilution from the Apogee acquisition transaction.
Bullish Signals
Revenue grew 10.2% YoY to $16.99B in Q2 2026.
Skyrizi and Rinvoq generated $8.03B, exceeding Humira's peak.
Adjusted diluted EPS rose 22.9% YoY to $3.65.
Raised full-year 2026 guidance by ~$300M to $67.6B.
Acquired Apogee Therapeutics for $10.9B to expand immunology.
Risk Factors
Humira revenue fell 36.1% to $756M in Q2 2026 due to biosimilar exclusivity loss.
EPS guidance trimmed slightly reflecting dilution from Apogee acquisition transaction.
Substantial Allergan debt competes with buybacks for capital allocation.
Bullish Signals
Total net revenues grew 10.2% year over year to $16.99 billion in Q2 2026, demonstrating successful portfolio transition.
Skyrizi and Rinvoq generated a combined $8.03 billion in revenue for the quarter, comfortably exceeding Humira's peak performance.
Adjusted diluted EPS increased 22.9% year over year to $3.65, highlighting strong underlying cash flow generation.
The company raised full-year 2026 revenue guidance by approximately $300 million to roughly $67.6 billion.
AbbVie secured patent settlements extending US exclusivity for Rinvoq until April 2037, providing a decade-long planning horizon.
Skyrizi alone reached about $5.5 billion in quarterly revenue, up around 24% operationally from the prior year.
AbbVie agreed to acquire Apogee Therapeutics for roughly $10.9 billion to deepen its immunology franchise with a next-generation IL-13 antibody.
The company maintains an adjusted operating margin of 48.3%, reflecting the high-margin nature of its branded pharmaceutical business.
AbbVie declared a quarterly dividend of $1.73 per share, continuing its track record as a Dividend Aristocrat since inception.
Risk Factors
Humira revenue fell 36.1% operationally to $756 million in Q2 2026 following the loss of US exclusivity to biosimilars.
AbbVie trimmed adjusted diluted EPS guidance slightly to reflect anticipated dilution from the Apogee acquisition transaction.
The company carries substantial debt originating from the 2020 Allergan acquisition, which competes with buybacks for capital allocation.
This article presents a comparative investment analysis between pharmaceutical giants AbbVie (ABBV) and Bristol-Myers Squibb (BMY), evaluating their growth potential, financial performance, and risk profiles for investors targeting 2026. The author concludes that AbbVie is the superior pick due to its focused operational strategy, faster growth trajectory, and high-yielding dividend, positioning it as a stronger long-term investment compared to Bristol-Myers Squibb.
AbbVie reported Fiscal Year 2025 revenues of approximately $61.2 billion, representing an 8.6% year-over-year increase driven by the expansion of newer drug labels that offset erosion from legacy products. The company is successfully transitioning away from its dependence on Humira as biosimilar competition subsides, with its neuroscience portfolio accelerating growth and prospects looking promising following the recent patent cliff for its flagship immunology drug.
In contrast, Bristol-Myers Squibb saw a slight revenue decline of 0.2% to $48.2 billion in FY 2025, though it achieved a net income recovery of approximately $7.1 billion largely due to one-time charges. The company faces significant headwinds including expected market exclusivity losses for blockbuster drugs like Eliquis and Opdivo, global pricing restrictions, and dependence on new product launches to sustain growth in its oncology and cardiovascular segments.
The analysis highlights that while Bristol-Myers Squibb trades at a lower Forward P/E ratio suggesting slower growth expectations, AbbVie offers more enticing value through its dividend yield and improved outlook. The author notes that AbbVie recently raised its full-year guidance for the second time this year, reinforcing its positive momentum despite broader industry challenges like drug pricing reforms under the Inflation Reduction Act.
📊 Abbvie FY2025 revenue rose 8.6% to $61.2 billion.
💰 Bristol-Myers Squibb revenue dipped slightly but net income recovered.
🧬 Abbvie reduces Humira reliance while neuroscience portfolio accelerates.
⚠️ Bristol-Myers Squibb risks revenue decline from Eliquis and Opdivo exclusivity losses.
🏆 Author favors Abbvie for growth, yield, and focused strategy.
📊 AbbVie reported Fiscal Year 2025 revenues of $61.2 billion, an 8.6% increase driven by newer drug labels offsetting legacy product erosion.
💰 Bristol-Myers Squibb recorded a slight revenue decrease to $48.2 billion in FY 2025 but recovered net income to approximately $7.1 billion via one-time charges.
🧬 AbbVie is transitioning away from Humira dependence as biosimilar competition mostly passes, with its neuroscience portfolio accelerating growth.
⚠️ Bristol-Myers Squibb faces substantial revenue decline risks due to expected market exclusivity losses for blockbuster drugs Eliquis and Opdivo.
📈 AbbVie recently raised its full-year outlook for the second time this year, signaling strong operational momentum.
💸 Both companies offer consistent dividends and stable cash flows, making them attractive to income-seeking investors in the healthcare sector.
🏆 The author favors AbbVie over Bristol-Myers Squibb due to its focused strategy, faster growth rate, and higher dividend yield.
📉 Bristol-Myers Squibb trades at a lower Forward P/E ratio than AbbVie, reflecting market expectations of slower future growth.
⚖️ Both companies face industry-wide risks including patent expirations, competition from major rivals like Pfizer and Merck, and potential pricing pressures from the Inflation Reduction Act.
Patent expirations on key immunology drugs create ongoing revenue risks.
Rising competition from rivals like Pfizer threatens specialty medicine market share.
Inflation Reduction Act pricing pressures may impact future profitability.
Global reimbursement restrictions limit pricing flexibility and compress margins.
Clinical trial setbacks or regulatory delays risk next-generation pipeline growth.
Bullish Signals
AbbVie achieved an impressive 8.6% revenue growth in FY 2025 to reach $61.2 billion, driven by the successful expansion of newer drug labels.
The company has successfully navigated the Humira patent cliff with biosimilar competition mostly past, allowing its neuroscience portfolio to accelerate growth.
AbbVie recently raised its full-year financial outlook for the second time this year, demonstrating strong management confidence and operational execution.
AbbVie offers one of the most enticing dividends in the healthcare sector, providing significant value to income-focused investors.
The company maintains a focused operation strategy that is delivering better results compared to peers with more diversified but slower-growing portfolios.
Risk Factors
AbbVie faces ongoing risks from patent expirations on key immunology drugs and rising competition in the specialty medicine market against rivals like Pfizer.
The company may be impacted by potential pricing pressures resulting from government regulations under the Inflation Reduction Act.
Bristol-Myers Squibb contends with global pricing and reimbursement restrictions that limit its pricing flexibility and could compress margins.
The company faces long-term growth risks if there are setbacks in clinical trials or regulatory delays for its next-generation pipeline products.
Cantor Fitzgerald has raised its price target for AbbVie (NYSE: ABBV) from $265 to $285, maintaining an overweight rating. This follows a mixed landscape of recent analyst actions, including JPMorgan Chase increasing its target to $280 and DZ Bank upgrading the stock to a strong buy, while Wall Street Zen downgraded its rating to 'buy' and Citigroup kept a neutral stance.
The company reported strong financial results for the quarter ended July 31, with earnings per share of $3.65 beating the consensus estimate of $3.61. Revenue reached $16.99 billion, surpassing analyst expectations of $16.80 billion and representing a 10.2% year-over-year increase. The business achieved a net margin of 9.80%, though it recorded a negative return on equity of 466.39%.
AbbVie has set its Q3 2026 earnings guidance between $3.84 and $3.88 per share, with analysts averaging an expectation of $14.12 EPS for the current fiscal year. The company also declared a quarterly dividend of $1.73 payable on August 14th to shareholders of record as of July 15th, resulting in an annualized yield of 2.8% and a payout ratio of 195.48%. Institutional ownership remains high at 70.23%, with several hedge funds increasing their stakes during the second quarter.
📈 Cantor Fitzgerald raised AbbVie price target to $285.
📊 Q2 earnings beat estimates at $3.65 per share.
💰 Revenue reached $16.99 billion with 10.2% growth.
🎯 Q3 guidance set between $3.84 and $3.88 EPS.
💵 Dividend of $1.73 payable August 14th.
📈 Cantor Fitzgerald raised its price target for AbbVie from $265 to $285 while maintaining an overweight rating.
📊 The company reported Q2 earnings of $3.65 per share, beating the consensus estimate of $3.61 by $0.04.
💰 Revenue for the quarter reached $16.99 billion, exceeding analyst estimates of $16.80 billion.
📈 Year-over-year revenue growth was 10.2%, driven by strong performance across therapeutic areas.
🎯 AbbVie provided Q3 2026 earnings guidance ranging from $3.84 to $3.88 per share.
💵 A quarterly dividend of $1.73 will be paid on August 14th with an ex-dividend date of July 15th.
📉 The stock carries a negative return on equity of -466.39% for the reported quarter.
🏦 Institutional ownership stands at 70.23%, with several hedge funds increasing their holdings in Q2.
📊 Analyst consensus rating is 'Moderate Buy' with an average price target of $271.48.
🔬 AbbVie focuses on complex chronic conditions across immunology, oncology, neuroscience, and other areas.
Bullish Signals
Cantor Fitzgerald raised price target to $285.
AbbVie beat earnings with $3.65 EPS vs $3.61 consensus.
Revenue of $16.99B exceeded estimates of $16.80B.
Company achieved 10.2% year-over-year revenue increase.
Major banks like JPMorgan Chase issued upgrades.
Risk Factors
Negative ROE of -466.39% indicates significant leverage or accounting adjustments.
Dividend payout ratio of 195.48% exceeds current quarterly earnings.
Bullish Signals
Cantor Fitzgerald increased its price target to $285, signaling strong confidence in the company's near-term prospects.
AbbVie beat earnings expectations with $3.65 EPS compared to the consensus of $3.61.
Revenue of $16.99 billion exceeded analyst estimates of $16.80 billion, demonstrating solid top-line execution.
The company achieved a 10.2% year-over-year revenue increase, indicating sustained growth momentum.
Multiple major banks including JPMorgan Chase and DZ Bank have issued upgrades or maintained overweight ratings.
The board declared a $1.73 quarterly dividend, providing a 2.8% annualized yield to shareholders.
Several hedge funds, including ACT Advisors and Willner & Heller, increased their stakes during the second quarter.
Risk Factors
AbbVie reported a negative return on equity of -466.39%, indicating significant leverage or accounting adjustments affecting equity metrics.
The dividend payout ratio is 195.48%, which exceeds 100% and suggests the company is paying out more than its current quarterly earnings.
AbbVie (NYSE: ABBV) is highlighted as a compelling investment opportunity ahead of its July 31 Q2 earnings report, driven by strong financial metrics and successful product transitions. The company trades at a forward P/E of 18x with a PEG ratio of 0.43 and a low beta of 0.28, offering a 2.62% dividend yield that recently increased by 5.5% to $1.73 per share.
The core growth strategy relies on the blockbuster immunology drugs Skyrizi and Rinvoq, which combined generated $6.6 billion in Q1 revenue. Skyrizi sales reached $4.48 billion (up 30.9% YoY) while Rinvoq added $2.12 billion (up 23.3%), effectively replacing the declining Humira franchise. Management has raised full-year guidance for both drugs, projecting nearly $32 billion in combined annual sales.
AbbVie's financial performance significantly outpaces peers like Pfizer and Merck over the last five years, with a 164% gain compared to Pfizer's decline. The company successfully navigated the biosimilar competition that threatens Merck's Keytruda franchise, positioning itself as a leader in income generation and growth with low market volatility.
📈 Trades at 18x forward P/E with 0.28 beta for low volatility.
💰 Dividend raised 5.5% to $1.73/share yielding 2.62%.
🚀 Skyrizi and Rinvoq generated $6.6B combined Q1 revenue.
📊 EPS guidance raised to $14.08-$14.28 ahead of July report.
🛡️ New drugs projected to generate nearly $32B annually.
📈 AbbVie trades at a forward P/E of 18x with a PEG ratio of 0.43 and a beta of 0.28, indicating low volatility relative to the broader market.
💰 The quarterly dividend was raised 5.5% to $1.73 per share, resulting in an annualized yield of 2.62%.
🚀 Skyrizi and Rinvoq combined generated $6.6 billion in Q1 revenue, with Skyrizi alone reaching $4.48 billion.
📊 Management raised full-year EPS guidance to a range of $14.08 to $14.28 ahead of the July 31 earnings report.
🔬 Skyrizi sales grew 30.9% year-over-year while Rinvoq sales increased 23.3% in the first quarter.
🛡️ The company has successfully transitioned away from Humira, with new drugs projected to generate nearly $32 billion annually.
📉 AbbVie delivered a 164% five-year return, significantly outperforming Pfizer's negative 23% return over the same period.
🏆 Wall Street consensus target price is set at $267.79 with 16 Buy and 8 Strong Buy ratings from analysts.
⚖️ AbbVie offers a combination of income, growth, and low volatility compared to peers facing patent cliffs or biosimilar erosion.
Bullish Signals
PEG ratio of 0.43 suggests undervaluation relative to earnings growth.
Quarterly dividend raised 5.5% to $1.73, signaling strong cash flow.
Skyrizi and Rinvoq generated $6.6 billion in Q1 revenue.
Management raised full-year guidance for Skyrizi ($21.6B) and Rinvoq ($10.2B).
Stock achieved 164% five-year gain, vastly outperforming Pfizer's -23% return.
Bullish Signals
AbbVie trades at a PEG ratio of 0.43, suggesting the stock is undervalued relative to its earnings growth rate.
The company raised its quarterly dividend by 5.5% to $1.73, signaling strong cash flow and commitment to shareholder returns.
Skyrizi and Rinvoq combined generated $6.6 billion in Q1 revenue, demonstrating robust demand for the new growth engines.
Management raised full-year guidance for both Skyrizi ($21.6B) and Rinvoq ($10.2B), indicating confidence in future sales.
AbbVie achieved a 164% five-year gain, vastly outperforming competitor Pfizer which saw a -23% return over the same period.
The stock has a low beta of 0.28, providing downside protection and lower volatility compared to the S&P 500 average.
Analyst consensus target price of $267.79 is slightly above the current trading price of $265.52, reflecting positive sentiment.
AbbVie has successfully navigated the biosimilar valley that Merck is currently facing with its Keytruda franchise.
Your Privacy
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Measure audience engagement and site statistics to understand how our services are used (Google Analytics)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
You can accept all cookies or configure your preferences. You can change them at any time via the "Manage Cookies" link in the footer.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Analytics cookies
Help us understand how visitors interact with our website using Google Analytics. These cookies collect information anonymously.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
